Abstract
Individual-level variation in susceptibility to infection and transmissibility of infection can affect population-level dynamics in epidemic outbreaks. Prior work has incorporated independent variation in susceptibility or transmissibility of individuals into epidemic compartmental models. Here, we develop and assess a mathematical framework that includes covariation in susceptibility and transmissibility. We show that uncorrelated variation in susceptibility and transmissibility leads to an effective transmissibility distribution that has a constant coefficient of variation such that the epidemic dynamics match those with variation in susceptibility alone, providing a baseline for comparison across different correlation structures. Increasing the correlation between susceptibility and transmissibility increases both the speed and strength of the outbreak – and is indicative of outbreaks which might be strongly structured by contact rate variation. In contrast, negative correlations between susceptibility and transmissibility lead to overall weaker outbreaks – with the caveat that the strength of effective transmission increases over time. In either case, correlations can shift the transmissibility distribution, thereby modifying the speed of the epidemic as the susceptible population is depleted. Overall, this work demonstrates how (often unaccounted) covariation in susceptibility and transmission can shape the course of outbreaks and final outbreak sizes.
Highlights
Developed models incorporating susceptibility and transmissibility covariation.
Identified eigendistributions of the force of infection.
Uncorrelated transmissibility reduces to variation in susceptibility alone.
Positive correlations lead to increases in the basic reproduction number.
Positive correlations give faster, stronger, more likely outbreaks.
Effective transmission rates increase over time with negative correlations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the National Science Foundation (no. 2200269) to JSW, the Simons Foundation (no. 930382) to JSW, and support from the Charities in Aid Foundation, the Marier Cunningham Foundation, and the Chaires Blaise Pascal program of the Île-de-France region (Blaise Pascal Institute Chair of Excellence awarded to JSW).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data Availability
MATLAB (version 2023b and 2024a) code for the analysis performed in this manuscript is available at https://github.com/Jeremy-D-Harris/SIR_heterogeneity_project and is archived on Zenodo, doi:10.5281/zenodo.13891898.
https://github.com/Jeremy-D-Harris/SIR_heterogeneity_project
